Treats relapsing forms of multiple sclerosis (MS). ANDA 207979, held by Biocon Ltd. Fingolimod Hydrochloride.
As of Nov 16, 2026, ANDA 207979 (Fingolimod Hydrochloride), held by Biocon Ltd, was first approved by FDA on Dec 4, 2019, with 4 approved supplements and 0 published complete response letters.
Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 4, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fingolimod HydrochlorideEQ 0.5MG BASE · capsule;oral | Fingolimod Hydrochloride | Rx |
| Mar 12, 2026 | Supplement 8Labeling · Standard review | Approved | None posted |
| Mar 12, 2026 | Supplement 11Labeling · Standard review | Approved | None posted |
| Apr 16, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 9, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Dec 4, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters